CALAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Calan, and what generic alternatives are available?
Calan is a drug marketed by Gd Searle Llc and Pfizer and is included in three NDAs.
The generic ingredient in CALAN is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Calan
A generic version of CALAN was approved as verapamil hydrochloride by EXELA PHARMA on March 30th, 1984.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CALAN?
- What are the global sales for CALAN?
- What is Average Wholesale Price for CALAN?
Summary for CALAN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Patent Applications: | 2,568 |
| Drug Prices: | Drug price information for CALAN |
| DailyMed Link: | CALAN at DailyMed |
US Patents and Regulatory Information for CALAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gd Searle Llc | CALAN | verapamil hydrochloride | INJECTABLE;INJECTION | 019038-001 | Mar 30, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | CALAN SR | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019152-002 | Dec 15, 1989 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | CALAN | verapamil hydrochloride | TABLET;ORAL | 018817-002 | Sep 10, 1984 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
